famotidine has been researched along with Neoplasms in 8 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The findings indicated a significant effect of famotidine on reduction of thrombocytopenia among intervention group compared to control group (P < 0." | 5.69 | Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial. ( Moghaddam, ZK; Rezaeejam, H; Rostami, M; Sadeghi, A; Yelghi, O; Zeraatchi, A, 2023) |
| "Omeprazole was not helpful in reducing the frequency or severity of GI AEs and was associated with more frequent and severer GI AEs in dogs with cancer treated with single agent piroxicam." | 3.01 | A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine. ( Fulkerson, CM; Moore, GE; Shaevitz, MH, 2021) |
| "Famotidine resulted in lower AUC while food had no effect." | 2.80 | Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. ( Bendell, JC; Clary, DO; Dickson, MA; Edelman, G; Gordon, MS; Johnston, SH; Kudchadkar, RR; LoRusso, PM; Schwartz, GK, 2015) |
| "Type of cancer, treatment, age, and BMI were not significant predictors of bone pain." | 1.46 | Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. ( Abrams, M; Gavioli, E, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, CH | 1 |
| Chen, II | 1 |
| Chen, CH | 1 |
| Tseng, YT | 1 |
| Rostami, M | 1 |
| Yelghi, O | 1 |
| Moghaddam, ZK | 1 |
| Zeraatchi, A | 1 |
| Rezaeejam, H | 1 |
| Sadeghi, A | 1 |
| Shaevitz, MH | 1 |
| Moore, GE | 1 |
| Fulkerson, CM | 1 |
| Dickson, MA | 1 |
| Gordon, MS | 1 |
| Edelman, G | 1 |
| Bendell, JC | 1 |
| Kudchadkar, RR | 1 |
| LoRusso, PM | 1 |
| Johnston, SH | 1 |
| Clary, DO | 1 |
| Schwartz, GK | 1 |
| Gavioli, E | 1 |
| Abrams, M | 1 |
| Ogawa, M | 1 |
| Shinjo, T | 1 |
| Tei, Y | 1 |
| Morita, T | 1 |
| Tsunoda, T | 1 |
| Tanimura, H | 1 |
| Yamaue, H | 1 |
| Iwahashi, M | 1 |
| Tani, M | 1 |
| Tamai, M | 1 |
| Arii, K | 1 |
| Noguchi, K | 1 |
| Smith, T | 1 |
1 review available for famotidine and Neoplasms
| Article | Year |
|---|---|
Histamine type 2-receptor antagonists and cancer immunotherapy.
Topics: Cimetidine; Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Immunotherapy; N | 1990 |
Histamine type 2-receptor antagonists and cancer immunotherapy.
Topics: Cimetidine; Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Immunotherapy; N | 1990 |
4 trials available for famotidine and Neoplasms
| Article | Year |
|---|---|
Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial.
Topics: Cardia; Double-Blind Method; Famotidine; Humans; Iran; Neoplasms; Single-Blind Method; Thrombocytope | 2023 |
Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial.
Topics: Cardia; Double-Blind Method; Famotidine; Humans; Iran; Neoplasms; Single-Blind Method; Thrombocytope | 2023 |
A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine.
Topics: Animals; Dog Diseases; Dogs; Famotidine; Incidence; Neoplasms; Omeprazole; Piroxicam; Prospective St | 2021 |
A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine.
Topics: Animals; Dog Diseases; Dogs; Famotidine; Incidence; Neoplasms; Omeprazole; Piroxicam; Prospective St | 2021 |
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Carbamates; | 2015 |
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Carbamates; | 2015 |
Histamine type 2-receptor antagonists and cancer immunotherapy.
Topics: Cimetidine; Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Immunotherapy; N | 1990 |
Histamine type 2-receptor antagonists and cancer immunotherapy.
Topics: Cimetidine; Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Immunotherapy; N | 1990 |
4 other studies available for famotidine and Neoplasms
| Article | Year |
|---|---|
Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study.
Topics: Cohort Studies; Dimethylnitrosamine; Famotidine; Humans; Longitudinal Studies; Neoplasms; Proton Pum | 2022 |
Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study.
Topics: Cohort Studies; Dimethylnitrosamine; Famotidine; Humans; Longitudinal Studies; Neoplasms; Proton Pum | 2022 |
Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.
Topics: Aged; Antineoplastic Agents; Bone Diseases; Cohort Studies; Famotidine; Febrile Neutropenia; Female; | 2017 |
Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.
Topics: Aged; Antineoplastic Agents; Bone Diseases; Cohort Studies; Famotidine; Febrile Neutropenia; Female; | 2017 |
Uncommon underlying etiologies of reversible delirium in terminally ill cancer patients.
Topics: Aged; Anti-Ulcer Agents; Delirium; Famotidine; Female; Humans; Hyperammonemia; Male; Neoplasms; Pall | 2006 |
Uncommon underlying etiologies of reversible delirium in terminally ill cancer patients.
Topics: Aged; Anti-Ulcer Agents; Delirium; Famotidine; Female; Humans; Hyperammonemia; Male; Neoplasms; Pall | 2006 |
In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients.
Topics: Antigens, CD; Cytotoxicity, Immunologic; Famotidine; Humans; Immunotherapy, Adoptive; In Vitro Techn | 1992 |
In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients.
Topics: Antigens, CD; Cytotoxicity, Immunologic; Famotidine; Humans; Immunotherapy, Adoptive; In Vitro Techn | 1992 |